Abstract
Background: The serotonin 2B receptor subtype (5-HT2BR), located in central nervous system (CNS), cardiovascular system (CVS) and the gastrointestinal tract (GIT), is an important target for the treatment of migraine, obesity and irritable bowel syndrome. 5-HT2BR is necessary for the myocardial cell proliferation and differentiation at the embroyonic stage for healthy development of heart. Recently, its involvement in drug induced valvulopathy and other myocardial disorders, have paved a way for selective antagonist for the treatment of cardiac disorders.
Conclusion: The current review summarizes the limited progress made in the past decade for design and development of 5-HT2BR antagonists for the treatment of disorders related to heart. We focus primarily on the different scaffolds reported in both manuscripts and patents, that have led to selectivity for 5-HT2B over subtype 5-HT2A/2C. Opportunities in cardiovascular drug development for novel 5-HT2BR antagonists are also presented.
Keywords: Serotonin inhibitors, 5-HT2BR antagonist, valvulopathy, pulmonary arterial hypertension, tryptophan platelet, platelet aggregation.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists
Volume: 17 Issue: 2
Author(s): Komal Padhariya, Richie Bhandare*, Daniel Canney and Vinay Velingkar
Affiliation:
- Department of Pharmaceutical Chemistry & Pharmacognosy, College of Pharmacy & Health Sciences, Ajman University, Ajman,United Arab Emirates
Keywords: Serotonin inhibitors, 5-HT2BR antagonist, valvulopathy, pulmonary arterial hypertension, tryptophan platelet, platelet aggregation.
Abstract: Background: The serotonin 2B receptor subtype (5-HT2BR), located in central nervous system (CNS), cardiovascular system (CVS) and the gastrointestinal tract (GIT), is an important target for the treatment of migraine, obesity and irritable bowel syndrome. 5-HT2BR is necessary for the myocardial cell proliferation and differentiation at the embroyonic stage for healthy development of heart. Recently, its involvement in drug induced valvulopathy and other myocardial disorders, have paved a way for selective antagonist for the treatment of cardiac disorders.
Conclusion: The current review summarizes the limited progress made in the past decade for design and development of 5-HT2BR antagonists for the treatment of disorders related to heart. We focus primarily on the different scaffolds reported in both manuscripts and patents, that have led to selectivity for 5-HT2B over subtype 5-HT2A/2C. Opportunities in cardiovascular drug development for novel 5-HT2BR antagonists are also presented.
Export Options
About this article
Cite this article as:
Padhariya Komal , Bhandare Richie *, Canney Daniel and Velingkar Vinay , Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists, Cardiovascular & Hematological Disorders-Drug Targets 2017; 17 (2) . https://dx.doi.org/10.2174/1871529X17666170703115111
DOI https://dx.doi.org/10.2174/1871529X17666170703115111 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patented Aptamers for C-Reactive Protein Detection: A Review About their Use in Clinical Diagnostics
Recent Patents on DNA & Gene Sequences Determinants of Use of Long-term Continuous Electrocardiographic Monitoring for Acute Ischemic Stroke Patients without Atrial Fibrillation at Baseline
Current Neurovascular Research Therapeutic Use of Calcitriol
Current Vascular Pharmacology Poor Nutrition with Aging: an “Oxidatively Stressing” Condition
Current Nutrition & Food Science Patient Attitudes Toward Western Medicine and the Future of Chinese Medicine for Spondyloarthritis
Current Rheumatology Reviews Targeting Nitrosative Stress for Neurovascular Protection: New Implications in Brain Diseases
Current Drug Targets Quality Control of Fingerprint of Radix Astragali by High-Performance Liquid Chromatography Coupled with Chemometric Methods
Current Pharmaceutical Analysis Clopidogrel in Secondary Ischemic Stroke Prevention
Recent Patents on Cardiovascular Drug Discovery 20-Hydroxyeicosatetraenoic Acid is a Potential Therapeutic Target in Cardiovascular Diseases
Current Drug Metabolism Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Acute Respiratory Failure in Obstetric Patients
Current Women`s Health Reviews Relationships Between White Matter Hyperintensities, Cerebral Amyloid Angiopathy and Dementia in a Population-based Sample of the Oldest Old
Current Alzheimer Research Editorial [Hot Topic: Opportunities and Potential Challenges for the Treatment of Metabolic Syndrome (Guest Editors: Kak-Shan Shia and Yu-Sheng Chao)]
Current Topics in Medicinal Chemistry Central Blood Pressure in Chronic Kidney Disease: Latest Evidence and Clinical Relevance
Current Hypertension Reviews Fetal Arterial Changes in Response to Maternal Cigarette Smoking: Revisiting the Natural History of the Earliest Stage of Atherosclerosis
Current Cardiology Reviews Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Serotonin-2 Receptor Agonists as Novel Ocular Hypotensive Agents and their Cellular and Molecular Mechanisms of Action: Novel Drug Targets for Glaucoma Treatment
Current Drug Targets Contextualizing Genetics for Regional Heart Failure Care
Current Cardiology Reviews Hereditary Haemorrhagic Teleangiectasia: Diagnostic Imaging of Visceral Involvement
Current Pharmaceutical Design Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine